FirstWord

Dazodalibep met its primary endpoint of reducing systemic disease activity at week 48 in the Phase III OASIZ 301 study.

AI Structural Biology Network members AbbVie, AstraZeneca, Bristol Myers Squibb and J&J are working on a new initiative to support virtual screening and lead optimisation.

The company lined up for an IPO the same day it signed an AI drug discovery deal with AbbVie.

The RNA-targeted drug led to significant improvement versus placebo on the primary endpoint assessing functional impairment and survival in patients with FUS-ALS.

Targets identified through the deal, potentially worth over $1 billion, could fuel ADCs, T-cell engagers and multispecifics.

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatolog...

Rapid Oral presentation will report initial Phase I data for ISM6331 in patients with advanced solid tumorsFDA Fast Track- and Orphan Drug-designated program reflects Insilico’s strategy to advance AI...

DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery a...

HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus ChemotherapyFirst Phase III Ivonescimab Readout beyond NSCLC ...

BOSTON, Sept. 22, 2026 /PRNewswire/ -- Blue Earth Diagnostics, part of the Bracco Group and recognized leader in the development and commercialization of innovative positron emission tomography (PET) ...